Amedisys (NASDAQ:AMED - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, July 23rd. Analysts expect Amedisys to post earnings of $1.39 per share and revenue of $614.61 million for the quarter.
Amedisys (NASDAQ:AMED - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. Amedisys had a net margin of 3.79% and a return on equity of 12.52%. The firm had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. During the same period in the previous year, the firm posted $1.03 EPS. The company's revenue for the quarter was up 4.1% compared to the same quarter last year. On average, analysts expect Amedisys to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Amedisys Trading Down 0.3%
Shares of NASDAQ AMED opened at $97.51 on Wednesday. The firm has a 50 day moving average price of $95.90 and a two-hundred day moving average price of $93.61. The stock has a market cap of $3.20 billion, a P/E ratio of 35.98, a price-to-earnings-growth ratio of 1.33 and a beta of 0.94. Amedisys has a 52-week low of $82.15 and a 52-week high of $98.95. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.29 and a current ratio of 1.29.
Institutional Investors Weigh In On Amedisys
A number of institutional investors have recently modified their holdings of AMED. Empowered Funds LLC boosted its position in Amedisys by 10.1% during the first quarter. Empowered Funds LLC now owns 3,854 shares of the health services provider's stock valued at $357,000 after acquiring an additional 354 shares during the last quarter. Great Lakes Advisors LLC acquired a new position in shares of Amedisys in the 1st quarter valued at about $214,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Amedisys by 9.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,990 shares of the health services provider's stock valued at $184,000 after purchasing an additional 176 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Amedisys by 98.3% during the 1st quarter. AQR Capital Management LLC now owns 13,410 shares of the health services provider's stock valued at $1,242,000 after purchasing an additional 6,646 shares in the last quarter. 94.36% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the company. Wall Street Zen downgraded Amedisys from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 24th. Royal Bank Of Canada reissued an "outperform" rating and issued a $100.00 price target on shares of Amedisys in a research note on Wednesday, April 16th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $100.75.
View Our Latest Stock Report on AMED
About Amedisys
(
Get Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
